AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
trihexyphenidyl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| vasodilators | 2745 | 144-11-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.63 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.601 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.057 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 26.669 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 12.274 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 11.740 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 27 | % | High | 1 |
| herg | hERG pIC50 | 5.341 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 4.276 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 15.276 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 15.430 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,SIK3,TEK,TGFBR1 | 36 | |||
| kinase-selectivity-class | AXL,GRK2,PDK4 | 3 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.527 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.303 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 78.343 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 14.550 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.099 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 25.830 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.478 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 195.434 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 35.040 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 17.750 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 628.058 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 13, 1949 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dystonia | 141.30 | 26.05 | 47 | 4671 | 16772 | 90606957 |
| Drug interaction | 131.15 | 26.05 | 111 | 4607 | 276342 | 90347387 |
| Dyskinesia | 105.86 | 26.05 | 47 | 4671 | 36487 | 90587242 |
| Coma | 104.46 | 26.05 | 58 | 4660 | 72574 | 90551155 |
| Tardive dyskinesia | 97.62 | 26.05 | 32 | 4686 | 10898 | 90612831 |
| Extrapyramidal disorder | 77.90 | 26.05 | 30 | 4688 | 16273 | 90607456 |
| Neuroleptic malignant syndrome | 76.51 | 26.05 | 29 | 4689 | 15067 | 90608662 |
| Hallucinations, mixed | 72.37 | 26.05 | 22 | 4696 | 5867 | 90617862 |
| Parkinsonism | 71.21 | 26.05 | 27 | 4691 | 14038 | 90609691 |
| Suicide attempt | 64.02 | 26.05 | 43 | 4675 | 75356 | 90548373 |
| Urinary retention | 62.16 | 26.05 | 33 | 4685 | 37711 | 90586018 |
| Toxicity to various agents | 61.15 | 26.05 | 75 | 4643 | 287771 | 90335958 |
| Muscle rigidity | 60.14 | 26.05 | 24 | 4694 | 14285 | 90609444 |
| Intentional overdose | 57.76 | 26.05 | 44 | 4674 | 93790 | 90529939 |
| Sinus tachycardia | 55.80 | 26.05 | 28 | 4690 | 28485 | 90595244 |
| Cognitive disorder | 55.15 | 26.05 | 38 | 4680 | 69369 | 90554360 |
| Tremor | 53.68 | 26.05 | 52 | 4666 | 153121 | 90470608 |
| Somnolence | 51.85 | 26.05 | 59 | 4659 | 209025 | 90414704 |
| Myoclonus | 50.22 | 26.05 | 23 | 4695 | 19145 | 90604584 |
| Pneumonia aspiration | 48.92 | 26.05 | 29 | 4689 | 40911 | 90582818 |
| Disorientation | 46.91 | 26.05 | 29 | 4689 | 44085 | 90579644 |
| Hallucination | 45.20 | 26.05 | 33 | 4685 | 65926 | 90557803 |
| Hyperchloraemia | 43.82 | 26.05 | 10 | 4708 | 878 | 90622851 |
| Apraxia | 43.62 | 26.05 | 12 | 4706 | 2250 | 90621479 |
| Mydriasis | 42.45 | 26.05 | 19 | 4699 | 14993 | 90608736 |
| Perseveration | 42.34 | 26.05 | 8 | 4710 | 277 | 90623452 |
| Intentional product misuse | 42.34 | 26.05 | 36 | 4682 | 89568 | 90534161 |
| Hyperreflexia | 41.89 | 26.05 | 15 | 4703 | 6642 | 90617087 |
| Speech disorder | 41.09 | 26.05 | 27 | 4691 | 45558 | 90578171 |
| Hypernatraemia | 40.33 | 26.05 | 16 | 4702 | 9371 | 90614358 |
| Transient aphasia | 39.89 | 26.05 | 6 | 4712 | 49 | 90623680 |
| Schizophrenia | 39.39 | 26.05 | 18 | 4700 | 14896 | 90608833 |
| Drug abuse | 38.73 | 26.05 | 33 | 4685 | 82314 | 90541415 |
| Oculogyric crisis | 38.04 | 26.05 | 11 | 4707 | 2468 | 90621261 |
| Salivary hypersecretion | 37.34 | 26.05 | 15 | 4703 | 9077 | 90614652 |
| Hallucination, auditory | 35.16 | 26.05 | 17 | 4701 | 15958 | 90607771 |
| Abulia | 35.07 | 26.05 | 8 | 4710 | 701 | 90623028 |
| Overdose | 33.26 | 26.05 | 41 | 4677 | 157668 | 90466061 |
| Drug screen false positive | 32.80 | 26.05 | 8 | 4710 | 935 | 90622794 |
| Macroprolactinaemia | 31.41 | 26.05 | 4 | 4714 | 7 | 90623722 |
| Delusion | 31.28 | 26.05 | 15 | 4703 | 13825 | 90609904 |
| Ataxia | 30.33 | 26.05 | 16 | 4702 | 18026 | 90605703 |
| Onychophagia | 30.10 | 26.05 | 5 | 4713 | 81 | 90623648 |
| Off label use | 29.41 | 26.05 | 124 | 4594 | 1102128 | 89521601 |
| Inappropriate antidiuretic hormone secretion | 29.16 | 26.05 | 16 | 4702 | 19489 | 90604240 |
| Pain | 29.12 | 26.05 | 8 | 4710 | 996333 | 89627396 |
| Cytopenia | 27.99 | 26.05 | 15 | 4703 | 17434 | 90606295 |
| Depressed level of consciousness | 27.92 | 26.05 | 26 | 4692 | 72758 | 90550971 |
| Drug ineffective for unapproved indication | 27.89 | 26.05 | 25 | 4693 | 66619 | 90557110 |
| Rhabdomyolysis | 27.12 | 26.05 | 22 | 4696 | 51234 | 90572495 |
| Persecutory delusion | 27.06 | 26.05 | 9 | 4709 | 3199 | 90620530 |
| Locked-in syndrome | 26.77 | 26.05 | 6 | 4712 | 486 | 90623243 |
| Electrocardiogram QT prolonged | 26.10 | 26.05 | 25 | 4693 | 72431 | 90551298 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Coma | 160.78 | 25.44 | 103 | 6830 | 53451 | 42560951 |
| Extrapyramidal disorder | 142.27 | 25.44 | 64 | 6869 | 16348 | 42598054 |
| Brain scan abnormal | 140.64 | 25.44 | 34 | 6899 | 1205 | 42613197 |
| Cerebral artery thrombosis | 140.37 | 25.44 | 34 | 6899 | 1215 | 42613187 |
| Neuroleptic malignant syndrome | 128.81 | 25.44 | 65 | 6868 | 21407 | 42592995 |
| Wrong patient received product | 125.62 | 25.44 | 39 | 6894 | 3544 | 42610858 |
| Areflexia | 107.50 | 25.44 | 35 | 6898 | 3708 | 42610694 |
| Dystonia | 101.75 | 25.44 | 47 | 6886 | 12743 | 42601659 |
| Hallucination | 92.89 | 25.44 | 76 | 6857 | 57431 | 42556971 |
| Respiratory distress | 86.50 | 25.44 | 64 | 6869 | 41756 | 42572646 |
| Somnolence | 81.18 | 25.44 | 107 | 6826 | 140998 | 42473404 |
| Failure to suspend medication | 77.62 | 25.44 | 17 | 6916 | 385 | 42614017 |
| Hemiplegia | 72.31 | 25.44 | 32 | 6901 | 7847 | 42606555 |
| Tardive dyskinesia | 63.15 | 25.44 | 28 | 6905 | 6896 | 42607506 |
| Facial paralysis | 58.14 | 25.44 | 32 | 6901 | 12531 | 42601871 |
| Drug abuse | 56.43 | 25.44 | 77 | 6856 | 104694 | 42509708 |
| Parkinsonism | 54.57 | 25.44 | 29 | 6904 | 10594 | 42603808 |
| Ischaemic stroke | 52.74 | 25.44 | 37 | 6896 | 22196 | 42592206 |
| Toxicity to various agents | 50.02 | 25.44 | 113 | 6820 | 229023 | 42385379 |
| Disease recurrence | 47.39 | 25.44 | 39 | 6894 | 29639 | 42584763 |
| Antipsychotic drug level increased | 46.22 | 25.44 | 20 | 6913 | 4646 | 42609756 |
| Dyskinesia | 46.15 | 25.44 | 36 | 6897 | 25354 | 42589048 |
| Accidental death | 43.42 | 25.44 | 17 | 6916 | 3066 | 42611336 |
| Delusion | 43.27 | 25.44 | 28 | 6905 | 14706 | 42599696 |
| Pneumonia aspiration | 40.16 | 25.44 | 45 | 6888 | 50033 | 42564369 |
| Drug interaction | 37.87 | 25.44 | 112 | 6821 | 266887 | 42347515 |
| Catatonia | 37.70 | 25.44 | 19 | 6914 | 6220 | 42608182 |
| Salivary hypersecretion | 37.67 | 25.44 | 23 | 6910 | 10920 | 42603482 |
| Faecaloma | 37.61 | 25.44 | 19 | 6914 | 6251 | 42608151 |
| Tremor | 37.45 | 25.44 | 61 | 6872 | 96868 | 42517534 |
| Rhabdomyolysis | 37.01 | 25.44 | 54 | 6879 | 77965 | 42536437 |
| Parkinsonism hyperpyrexia syndrome | 36.40 | 25.44 | 9 | 6924 | 350 | 42614052 |
| Schizophrenia | 33.34 | 25.44 | 21 | 6912 | 10529 | 42603873 |
| Cerebral amyloid angiopathy | 33.23 | 25.44 | 8 | 6925 | 278 | 42614124 |
| Muscle rigidity | 33.17 | 25.44 | 22 | 6911 | 12037 | 42602365 |
| Oculogyric crisis | 33.09 | 25.44 | 12 | 6921 | 1753 | 42612649 |
| Parkinsonian rest tremor | 32.07 | 25.44 | 8 | 6925 | 323 | 42614079 |
| Delirium | 30.37 | 25.44 | 40 | 6893 | 52479 | 42561923 |
| Diarrhoea | 30.11 | 25.44 | 19 | 6914 | 460830 | 42153572 |
| Prothrombin level decreased | 29.68 | 25.44 | 10 | 6923 | 1176 | 42613226 |
| Dysarthria | 28.92 | 25.44 | 34 | 6899 | 39773 | 42574629 |
| Miosis | 28.71 | 25.44 | 21 | 6912 | 13425 | 42600977 |
| White blood cell count increased | 28.67 | 25.44 | 36 | 6897 | 45051 | 42569351 |
| Akathisia | 28.58 | 25.44 | 19 | 6914 | 10432 | 42603970 |
| Salivary gland cancer stage IV | 28.36 | 25.44 | 5 | 6928 | 34 | 42614368 |
| Respiratory failure | 27.66 | 25.44 | 63 | 6870 | 128069 | 42486333 |
| Poisoning | 27.05 | 25.44 | 21 | 6912 | 14678 | 42599724 |
| Colitis ischaemic | 26.97 | 25.44 | 16 | 6917 | 7210 | 42607192 |
| Hallucination, auditory | 26.84 | 25.44 | 21 | 6912 | 14843 | 42599559 |
| Spleen congestion | 26.61 | 25.44 | 7 | 6926 | 350 | 42614052 |
| Hepatitis acute | 26.21 | 25.44 | 17 | 6916 | 8958 | 42605444 |
| Fatigue | 25.75 | 25.44 | 20 | 6913 | 435621 | 42178781 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Coma | 262.18 | 23.02 | 157 | 10908 | 117712 | 110460522 |
| Dystonia | 232.54 | 23.02 | 90 | 10975 | 25715 | 110552519 |
| Extrapyramidal disorder | 229.67 | 23.02 | 92 | 10973 | 28775 | 110549459 |
| Neuroleptic malignant syndrome | 205.11 | 23.02 | 89 | 10976 | 33970 | 110544264 |
| Tardive dyskinesia | 153.75 | 23.02 | 56 | 11009 | 13523 | 110564711 |
| Drug interaction | 151.17 | 23.02 | 216 | 10849 | 499967 | 110078267 |
| Brain scan abnormal | 143.65 | 23.02 | 33 | 11032 | 1538 | 110576696 |
| Dyskinesia | 139.41 | 23.02 | 78 | 10987 | 51368 | 110526866 |
| Cerebral artery thrombosis | 136.41 | 23.02 | 32 | 11033 | 1636 | 110576598 |
| Parkinsonism | 127.11 | 23.02 | 56 | 11009 | 22131 | 110556103 |
| Somnolence | 124.67 | 23.02 | 151 | 10914 | 297298 | 110280936 |
| Hallucination | 123.48 | 23.02 | 93 | 10972 | 101339 | 110476895 |
| Wrong patient received product | 104.29 | 23.02 | 35 | 11030 | 6639 | 110571595 |
| Drug abuse | 103.33 | 23.02 | 107 | 10958 | 177304 | 110400930 |
| Toxicity to various agents | 101.20 | 23.02 | 176 | 10889 | 480379 | 110097855 |
| Areflexia | 99.87 | 23.02 | 34 | 11031 | 6735 | 110571499 |
| Muscle rigidity | 86.39 | 23.02 | 44 | 11021 | 23987 | 110554247 |
| Respiratory distress | 85.67 | 23.02 | 64 | 11001 | 68810 | 110509424 |
| Pneumonia aspiration | 84.74 | 23.02 | 68 | 10997 | 81165 | 110497069 |
| Tremor | 81.91 | 23.02 | 101 | 10964 | 202131 | 110376103 |
| Salivary hypersecretion | 80.92 | 23.02 | 38 | 11027 | 17383 | 110560851 |
| Failure to suspend medication | 76.80 | 23.02 | 16 | 11049 | 470 | 110577764 |
| Oculogyric crisis | 75.69 | 23.02 | 24 | 11041 | 3808 | 110574426 |
| Rhabdomyolysis | 74.38 | 23.02 | 75 | 10990 | 120326 | 110457908 |
| Suicide attempt | 64.94 | 23.02 | 65 | 11000 | 103329 | 110474905 |
| Catatonia | 63.03 | 23.02 | 28 | 11037 | 11272 | 110566962 |
| Antipsychotic drug level increased | 61.50 | 23.02 | 24 | 11041 | 6991 | 110571243 |
| Ischaemic stroke | 59.62 | 23.02 | 42 | 11023 | 41221 | 110537013 |
| Urinary retention | 59.55 | 23.02 | 52 | 11013 | 69631 | 110508603 |
| Delusion | 58.88 | 23.02 | 34 | 11031 | 23721 | 110554513 |
| Disorientation | 56.93 | 23.02 | 51 | 11014 | 70620 | 110507614 |
| Hallucinations, mixed | 56.52 | 23.02 | 24 | 11041 | 8669 | 110569565 |
| Hallucination, auditory | 55.56 | 23.02 | 34 | 11031 | 26363 | 110551871 |
| Schizophrenia | 53.46 | 23.02 | 31 | 11034 | 21795 | 110556439 |
| Facial paralysis | 53.05 | 23.02 | 32 | 11033 | 24182 | 110554052 |
| Hemiplegia | 52.23 | 23.02 | 31 | 11034 | 22751 | 110555483 |
| Diarrhoea | 51.44 | 23.02 | 25 | 11040 | 1139480 | 109438754 |
| Drug screen false positive | 50.92 | 23.02 | 14 | 11051 | 1355 | 110576879 |
| Pain | 49.48 | 23.02 | 17 | 11048 | 954938 | 109623296 |
| Cognitive disorder | 49.48 | 23.02 | 52 | 11013 | 87459 | 110490775 |
| Akathisia | 49.21 | 23.02 | 27 | 11038 | 17086 | 110561148 |
| Hypernatraemia | 48.17 | 23.02 | 27 | 11038 | 17806 | 110560428 |
| Sinus tachycardia | 47.99 | 23.02 | 38 | 11027 | 44455 | 110533779 |
| Faecaloma | 46.99 | 23.02 | 25 | 11040 | 14883 | 110563351 |
| Agitation | 44.98 | 23.02 | 56 | 11009 | 112995 | 110465239 |
| Behaviour disorder | 44.66 | 23.02 | 21 | 11044 | 9626 | 110568608 |
| Drug ineffective for unapproved indication | 44.25 | 23.02 | 53 | 11012 | 102785 | 110475449 |
| Intentional overdose | 43.94 | 23.02 | 60 | 11005 | 132441 | 110445793 |
| Psychotic disorder | 43.49 | 23.02 | 38 | 11027 | 50899 | 110527335 |
| Delirium | 43.06 | 23.02 | 60 | 11005 | 134965 | 110443269 |
| Overdose | 41.91 | 23.02 | 80 | 10985 | 233714 | 110344520 |
| Arthralgia | 41.90 | 23.02 | 13 | 11052 | 779619 | 109798615 |
| Disease recurrence | 41.48 | 23.02 | 40 | 11025 | 60744 | 110517490 |
| Respiratory depression | 40.36 | 23.02 | 30 | 11035 | 31971 | 110546263 |
| Accidental death | 39.93 | 23.02 | 16 | 11049 | 4993 | 110573241 |
| Confusional state | 39.89 | 23.02 | 120 | 10945 | 468560 | 110109674 |
| Speech disorder | 39.18 | 23.02 | 39 | 11026 | 61530 | 110516704 |
| Poisoning | 38.31 | 23.02 | 28 | 11037 | 29077 | 110549157 |
| Fatigue | 37.47 | 23.02 | 40 | 11025 | 1215918 | 109362316 |
| Intentional product misuse | 36.46 | 23.02 | 55 | 11010 | 132849 | 110445385 |
| Poisoning deliberate | 36.18 | 23.02 | 26 | 11039 | 26305 | 110551929 |
| Parkinsonism hyperpyrexia syndrome | 35.89 | 23.02 | 9 | 11056 | 609 | 110577625 |
| Altered state of consciousness | 35.74 | 23.02 | 36 | 11029 | 57590 | 110520644 |
| Dysarthria | 35.60 | 23.02 | 43 | 11022 | 84078 | 110494156 |
| Mydriasis | 35.41 | 23.02 | 24 | 11041 | 22133 | 110556101 |
| White blood cell count increased | 35.40 | 23.02 | 46 | 11019 | 96796 | 110481438 |
| On and off phenomenon | 34.81 | 23.02 | 14 | 11051 | 4410 | 110573824 |
| Hallucination, visual | 34.72 | 23.02 | 30 | 11035 | 39575 | 110538659 |
| Parkinsonian rest tremor | 34.43 | 23.02 | 8 | 11057 | 392 | 110577842 |
| Perseveration | 33.91 | 23.02 | 8 | 11057 | 419 | 110577815 |
| Hyperchloraemia | 33.51 | 23.02 | 10 | 11055 | 1296 | 110576938 |
| Psychiatric symptom | 33.48 | 23.02 | 17 | 11048 | 9196 | 110569038 |
| Miosis | 33.21 | 23.02 | 23 | 11042 | 21960 | 110556274 |
| Abnormal behaviour | 33.07 | 23.02 | 29 | 11036 | 39010 | 110539224 |
| Hyperammonaemia | 32.30 | 23.02 | 19 | 11046 | 13713 | 110564521 |
| Wrong patient | 32.15 | 23.02 | 10 | 11055 | 1489 | 110576745 |
| Neutrophil count increased | 31.91 | 23.02 | 27 | 11038 | 34625 | 110543609 |
| Dysphagia | 31.85 | 23.02 | 56 | 11009 | 153544 | 110424690 |
| Cerebral amyloid angiopathy | 31.82 | 23.02 | 8 | 11057 | 547 | 110577687 |
| Torticollis | 31.74 | 23.02 | 12 | 11053 | 3209 | 110575025 |
| Aggression | 31.37 | 23.02 | 34 | 11031 | 59176 | 110519058 |
| Myoclonus | 30.98 | 23.02 | 26 | 11039 | 32972 | 110545262 |
| Apraxia | 30.63 | 23.02 | 12 | 11053 | 3528 | 110574706 |
| Prothrombin level decreased | 30.30 | 23.02 | 10 | 11055 | 1800 | 110576434 |
| Hyperreflexia | 30.16 | 23.02 | 16 | 11049 | 9469 | 110568765 |
| Persecutory delusion | 30.07 | 23.02 | 14 | 11051 | 6277 | 110571957 |
| Macroprolactinaemia | 28.80 | 23.02 | 4 | 11061 | 7 | 110578227 |
| Abdominal discomfort | 28.74 | 23.02 | 3 | 11062 | 393855 | 110184379 |
| Psychomotor skills impaired | 28.53 | 23.02 | 14 | 11051 | 7044 | 110571190 |
| Inappropriate antidiuretic hormone secretion | 28.38 | 23.02 | 25 | 11040 | 33826 | 110544408 |
| Off label use | 28.10 | 23.02 | 250 | 10815 | 1499935 | 109078299 |
| Salivary gland cancer stage IV | 27.72 | 23.02 | 5 | 11060 | 67 | 110578167 |
| Spleen congestion | 27.65 | 23.02 | 7 | 11058 | 492 | 110577742 |
| Hypersensitivity | 27.23 | 23.02 | 4 | 11061 | 403994 | 110174240 |
| Electrocardiogram QT prolonged | 26.96 | 23.02 | 43 | 11022 | 108917 | 110469317 |
| Cardiac death | 26.91 | 23.02 | 9 | 11056 | 1687 | 110576547 |
| Ataxia | 26.78 | 23.02 | 23 | 11042 | 30085 | 110548149 |
| Withdrawal syndrome | 25.96 | 23.02 | 23 | 11042 | 31357 | 110546877 |
| Treatment noncompliance | 25.63 | 23.02 | 34 | 11031 | 72956 | 110505278 |
| Sexually inappropriate behaviour | 25.60 | 23.02 | 7 | 11058 | 664 | 110577570 |
| Respiratory failure | 25.15 | 23.02 | 62 | 11003 | 215270 | 110362964 |
| Onychophagia | 25.01 | 23.02 | 5 | 11060 | 119 | 110578115 |
| Abulia | 25.01 | 23.02 | 8 | 11057 | 1305 | 110576929 |
| Sudden death | 24.52 | 23.02 | 20 | 11045 | 24375 | 110553859 |
| Intestinal obstruction | 23.82 | 23.02 | 28 | 11037 | 53199 | 110525035 |
| Logorrhoea | 23.59 | 23.02 | 11 | 11054 | 4946 | 110573288 |
| Disturbance in attention | 23.51 | 23.02 | 30 | 11035 | 61965 | 110516269 |
| Hypothermia | 23.21 | 23.02 | 20 | 11045 | 26282 | 110551952 |
| Rash | 23.08 | 23.02 | 29 | 11036 | 820935 | 109757299 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N04AA01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Tertiary amines |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| MeSH PA | D018727 | Muscarinic Antagonists |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
Related Drugs by ATC class:
N04AA Tertiary amines 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postencephalitic parkinsonism | indication | 19972008 | DOID:14332 |
| Parkinsonism | indication | 32798002 | |
| Parkinson's disease | indication | 49049000 | DOID:14330 |
| Extrapyramidal disease | indication | 76349003 | |
| Arteriosclerotic Parkinsonism | indication | ||
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Disorder of autonomic nervous system | contraindication | 15241006 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Shigellosis | contraindication | 36188001 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Dysuria | contraindication | 49650001 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Tardive dyskinesia | contraindication | 102449007 | |
| Dysentery | contraindication | 111939009 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Bleeding | contraindication | 131148009 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Fever | contraindication | 386661006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Disorder of coronary artery | contraindication | 414024009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | IC50 | 8.89 | CHEMBL | CHEMBL | |||
| Muscarinic acetylcholine receptor M2 | GPCR | IC50 | 7.73 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.35 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | IC50 | 8.17 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | IC50 | 7.99 | CHEMBL | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 5.61 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | IC50 | 7.58 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019959 | VUID |
| N0000148044 | NUI |
| D00787 | KEGG_DRUG |
| 52-49-3 | SECONDARY_CAS_RN |
| 4017900 | VANDF |
| 4019959 | VANDF |
| C0041009 | UMLSCUI |
| CHEBI:9720 | CHEBI |
| CHEMBL1490 | ChEMBL_ID |
| DB00376 | DRUGBANK_ID |
| CHEMBL1092 | ChEMBL_ID |
| D014282 | MESH_DESCRIPTOR_UI |
| 5572 | PUBCHEM_CID |
| 7315 | IUPHAR_LIGAND_ID |
| 1318 | INN_ID |
| 6RC5V8B7PO | UNII |
| 10811 | RXNORM |
| 2986 | MMSL |
| 5628 | MMSL |
| d00970 | MMSL |
| 001641 | NDDF |
| 004664 | NDDF |
| 2190009 | SNOMEDCT_US |
| 387120000 | SNOMEDCT_US |
| 387336005 | SNOMEDCT_US |
| 6RC5V8B7PO | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0658 | SOLUTION | 2 mg | ORAL | ANDA | 22 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5335 | TABLET | 2 mg | ORAL | ANDA | 9 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5337 | TABLET | 5 mg | ORAL | ANDA | 9 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2994 | TABLET | 2 mg | ORAL | ANDA | 9 sections |
| TRIHEXYPHENIDYL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-265 | TABLET | 2 mg | ORAL | ANDA | 10 sections |
| TRIHEXYPHENIDYL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-266 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0633 | TABLET | 2 mg | ORAL | ANDA | 10 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0634 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0696 | TABLET | 5 mg | ORAL | ANDA | 9 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54738-554 | TABLET | 2 mg | ORAL | ANDA | 10 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54738-555 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61748-054 | SYRUP | 2 mg | ORAL | ANDA | 21 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-065 | SOLUTION | 2 mg | ORAL | ANDA | 13 sections |
| Trihexyphenidyl Hydrochloride | Human Prescription Drug Label | 1 | 63850-0021 | TABLET | 2 mg | ORAL | ANDA | 19 sections |
| Trihexyphenidyl Hydrochloride | Human Prescription Drug Label | 1 | 63850-0022 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
| Trihexyphenidyl Hydrochloride | Human Prescription Drug Label | 1 | 64725-0161 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2782 | TABLET | 2 mg | ORAL | ANDA | 9 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69452-241 | TABLET | 2 mg | ORAL | ANDA | 20 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69452-242 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1140 | TABLET | 5 mg | ORAL | ANDA | 9 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1612 | TABLET | 2 mg | ORAL | ANDA | 9 sections |
| Trihexyphenidyl Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1657 | TABLET | 5 mg | ORAL | ANDA | 9 sections |
| TRIHEXYPHENIDYL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2409 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| TRIHEXYPHENIDYL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2410 | TABLET | 2 mg | ORAL | ANDA | 10 sections |
| TRIHEXYPHENIDYL HYDROCHLORIDE | Human Prescription Drug Label | 1 | 70954-211 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| TRIHEXYPHENIDYL HYDROCHLORIDE | Human Prescription Drug Label | 1 | 70954-212 | TABLET | 2 mg | ORAL | ANDA | 10 sections |